More Bad News For Pozen: Another Delay To Market For Yosprala
This article was originally published in The Pink Sheet Daily
Executive Summary
The company received a second “complete response” letter from FDA for Yosprala, its fixed-dose combination of aspirin and omeprazole, due to issues with the undisclosed third-party supplier.
You may also be interested in...
Keeping Track: Opdivo Dosing Simplified; Yosprala, Cuvitru Approved; Telotristat Review Lengthened
The latest drug development news and highlights from our FDA Performance Tracker.
Approval Might Be The Least Of Aralez's Challenges With Yosprala
If the aspirin/omeprazole finally gets approved on its third FDA review, Aralez then will face the challenge of positioning a prescription product against generic, over-the counter versions of both of its main components.
Sarepta Files DMD Gene Therapy, Seeking An Accelerated Path To Market
The company is seeking FDA accelerated approval of the closely watched gene therapy based on a surrogate marker and has proposed its fully enrolled Phase III trial to serve as a confirmatory study.